Atlas Trials

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Clinical trial NCT06364904 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06364904
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2025-10-01
Primary completion
2027-04-15
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.